Miguel Soneira MD MPH

Clinical Pharmacology

Physician

6717 El Dorado ParwaySuite 140McKinney, TX 75070
Phone+1 682-718-1778
Fax+1 281-206-2695

Dr. Soneira is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Soneira's full profile Already have an account?

Education & Training

Universidad Superior de Ciencias MedicasClass of 2013
IPUEC Gilberto Arocha GarciaB.S., 2003 - 2006

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Awards, Honors, & Recognition

Clinical Trial Service Company of the Year Life Sciences Review, 2022
Clinical Research Specialist of the Year 2020 GHP Healthcare and Pharmaceutical Awards, 2020
Golden Title for Academic Performance 2013

Clinical Trials

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Start of enrollment: 2019 Jul 25
Completed
Phase 2
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis Start of enrollment: 2018 Oct 08
Completed
Phase 2
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2021 May 06
TERMINATED
PHASE2